Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Improving survival in molecularly selected glioblastoma.

Stupp R, Lukas RV, Hegi ME.

Lancet. 2019 Feb 16;393(10172):615-617. doi: 10.1016/S0140-6736(18)33211-2. Epub 2019 Feb 14. No abstract available.

PMID:
30782332
2.

Association between response to primary treatments and MGMT status in glioblastoma.

Franceschi E, Tosoni A, Pozzati E, Brandes AA.

Expert Rev Anticancer Ther. 2008 Nov;8(11):1781-6. doi: 10.1586/14737140.8.11.1781. Review.

PMID:
18983238
3.

A silver lining on the horizon for glioblastoma.

Knisely JP, Baehring JM.

Lancet Oncol. 2009 May;10(5):434-5. doi: 10.1016/S1470-2045(09)70124-X. No abstract available.

PMID:
19410186
4.

Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.

Bell EH, Pugh SL, McElroy JP, Gilbert MR, Mehta M, Klimowicz AC, Magliocco A, Bredel M, Robe P, Grosu AL, Stupp R, Curran W Jr, Becker AP, Salavaggione AL, Barnholtz-Sloan JS, Aldape K, Blumenthal DT, Brown PD, Glass J, Souhami L, Lee RJ, Brachman D, Flickinger J, Won M, Chakravarti A.

JAMA Oncol. 2017 Jun 1;3(6):784-792. doi: 10.1001/jamaoncol.2016.6020.

5.

Glioblastoma in the elderly.

Chamberlain MC.

Cancer Treat Res. 2015;163:159-70. doi: 10.1007/978-3-319-12048-5_10. Review.

PMID:
25468231
6.

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group.

Lancet Oncol. 2009 May;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9.

PMID:
19269895
7.

Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation.

Kim SH, Yoo H, Chang JH, Kim CY, Chung DS, Kim SH, Park SH, Lee YS, Yang SH.

J Korean Med Sci. 2018 May 10;33(24):e167. doi: 10.3346/jkms.2018.33.e167. eCollection 2018 Jun 11.

8.

Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?

Hegi ME, Stupp R.

Neuro Oncol. 2015 Nov;17(11):1425-7. doi: 10.1093/neuonc/nov198. Epub 2015 Sep 15. No abstract available.

9.

MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.

Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK.

Pediatr Blood Cancer. 2007 Apr;48(4):403-7.

PMID:
16609952
10.

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).

Nabors LB, Mikkelsen T, Hegi ME, Ye X, Batchelor T, Lesser G, Peereboom D, Rosenfeld MR, Olsen J, Brem S, Fisher JD, Grossman SA; New Approaches to Brain Tumor Therapy (NABTT) Central Nervous System Consortium.

Cancer. 2012 Nov 15;118(22):5601-7. doi: 10.1002/cncr.27585. Epub 2012 Apr 19.

11.

Molecularly Targeted Drugs Plus Radiotherapy and Temozolomide Treatment for Newly Diagnosed Glioblastoma: A Meta-Analysis and Systematic Review.

Su J, Cai M, Li W, Hou B, He H, Ling C, Huang T, Liu H, Guo Y.

Oncol Res. 2016;24(2):117-28. doi: 10.3727/096504016X14612603423511. Review.

PMID:
27296952
12.

Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.

Thon N, Eigenbrod S, Grasbon-Frodl EM, Lutz J, Kreth S, Popperl G, Belka C, Kretzschmar HA, Tonn JC, Kreth FW.

J Neurol Neurosurg Psychiatry. 2011 Apr;82(4):441-6. doi: 10.1136/jnnp.2010.214593. Epub 2010 Sep 22.

PMID:
20861061
13.

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.

Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W; DIRECTOR Study Group.

Clin Cancer Res. 2015 May 1;21(9):2057-64. doi: 10.1158/1078-0432.CCR-14-2737. Epub 2015 Feb 5.

14.

The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.

McDonald KL, Rapkins RW, Olivier J, Zhao L, Nozue K, Lu D, Tiwari S, Kuroiwa-Trzmielina J, Brewer J, Wheeler HR, Hitchins MP.

Eur J Cancer. 2013 Jan;49(2):360-8. doi: 10.1016/j.ejca.2012.08.012. Epub 2012 Sep 10.

PMID:
22975219
15.

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team.

Lancet Oncol. 2014 Sep;15(10):1100-8. doi: 10.1016/S1470-2045(14)70379-1. Epub 2014 Aug 19.

16.

Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.

Gil Del Alcazar CR, Todorova PK, Habib AA, Mukherjee B, Burma S.

Mol Cancer Res. 2016 Oct;14(10):928-940. Epub 2016 Jun 29.

17.

Repair mechanisms help glioblastoma resist treatment.

Atkins RJ, Ng W, Stylli SS, Hovens CM, Kaye AH.

J Clin Neurosci. 2015 Jan;22(1):14-20. doi: 10.1016/j.jocn.2014.09.003. Epub 2014 Nov 28. Review.

PMID:
25444993
18.

Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery.

Stummer W, Meinel T, Ewelt C, Martus P, Jakobs O, Felsberg J, Reifenberger G.

J Neurooncol. 2012 May;108(1):89-97. doi: 10.1007/s11060-012-0798-3. Epub 2012 Feb 4.

19.

Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51.

Xipell E, Aragón T, Martínez-Velez N, Vera B, Idoate MA, Martínez-Irujo JJ, Garzón AG, Gonzalez-Huarriz M, Acanda AM, Jones C, Lang FF, Fueyo J, Gomez-Manzano C, Alonso MM.

Neuro Oncol. 2016 Aug;18(8):1109-19. doi: 10.1093/neuonc/now022. Epub 2016 Mar 6.

20.

Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.

Wang X, Chen JX, Liu JP, You C, Liu YH, Mao Q.

Ann Surg Oncol. 2014 Apr;21(4):1337-44. doi: 10.1245/s10434-013-3380-0. Epub 2013 Nov 19.

PMID:
24248532

Supplemental Content

Support Center